Efavirenz has been a mainstay of antiretroviral therapy (ART) for over 15 years in the US. Its association with neuropsychiatric side effects may influence clinical prescribing and management.
Methods
We included HIV-infected adults enrolled in care at seven sites across the US, who initiated combination ART between 1999 and 2015. We examined the proportion initiating and continuing on efavirenz, overall and by mental health status. Log binomial and Cox models were used to estimate associations between mental health, clinical and sociodemographic characteristics and initiating or switching from efavirenz as first-line ART.
Results
Of the 8,230 participants included, 3,710 (45%) initiated efavirenz. In multivariable analyses, prior mono-or dual-ART, ART initiation after 2006, being female, intravenous drug use, antidepressant prescription, previous mental health diagnosis and baseline CD4+ T-cell count >350 cells/mm3 were inversely associated with initiating efavirenz. Participants initiating efavirenz had a faster time to a regimen switch, compared with those initiating an efavirenz-free regimen (P-value <0.01). Among efavirenz initiators, starting efavirenz in more recent time periods and a previous mental health diagnosis were associated with faster time to switching from efavirenz. Despite this, 40–50% of participants with a previous mental health diagnosis initiated and continued on efavirenz for much of the follow-up period.
Conclusions
Multiple clinical factors, including mental health diagnoses, appeared to influence efavirenz use. While mental health diagnosis status and more recent treatment starts were associated with shorter duration of efavirenz therapy, a previous mental health diagnosis did not preclude efavirenz initiation or continuation in many participants.
References
1.
Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (Updated 8 April 2015. Accessed 11 October 2016.) Available from https://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL003400.pdf.
2.
Panel on Clinical Practices for Treatment of HIV Infection.Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents: Department of Health and Human Services and the Henry J. Kaiser Family Foundation. (Updated 5 May 1999. Accessed 11 November 2016.) Available from https://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL05051999011.pdf.
3.
RaffF., PozniakA.L., WainbergM.A.Has the time come to abandon efavirenz for first-line antiretroviral therapy?J Antimicrob Chemother2014; 69: 1742–1747.
4.
World Health Organization.Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach.2010. (Accessed 11 November 2016.) Available from http://www.who.int/hiv/pub/arv/adult2010/en.
5.
KrystJ., KawalecP., PilcA.Efavirenz-based regimens in antiretroviral-naive HIV-infected patients: a systematic review and meta-analysis of randomized controlled trials.PLoS One2015; 10: e0124279.
6.
CoovadiaA., AbramsE.J., StrehlauR.Efavirenz-based antiretroviral therapy among nevirapine-exposed HIV-infected children in South Africa: a randomized clinical trial.JAMA2015; 314: 1808–1817.
7.
IwujiC.C., Orne-GliemannJ., LarmarangeJ.Universal test and treat and the HIV epidemic in rural South Africa: a Phase 4, open-label, community cluster randomised trial.Lancet HIV2017; doi: 10.1016/S2352-3018(17)30205-9.
8.
MasimirembwaC., DandaraC., LeutscherP.D.Rolling out efavirenz for HIV precision medicine in Africa: are we ready for pharmacovigilance and tackling neuropsychiatric adverse effects?OMICS2016; 20: 575–580.
9.
SonderupM.W., MaughanD., GogelaN.Identification of a novel and severe pattern of efavirenz drug-induced liver injury in South Africa.AIDS2016; 30: 1483–1485.
10.
KenediC.A., GoforthH.W.A systematic review of the psychiatric side-effects of efavirenz.AIDS Behav2011; 15: 1803–1818.
11.
Sustiva (efavirenz).Package insert2013. Bristol–Myers SquibbPrinceton, NJ, USA.
12.
MollanK.R., SmurzynskiM., EronJ.J.Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.Ann Intern Med2014; 161: 1–10.
13.
Arenas-PintoA., GrundB., SharmaS.Increased risk of suicidal behaviour with use of efavirenz: results from the START Trial.AIDS. 18–22 July 2016, Durban, South Africa. Abstract THAB0202.
14.
NapoliA.A., WoodJ.J., CoumbisJ.J., SoitkarA.M., SeekinsD.W., TilsonH.H.No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database.J Int AIDS Soc2014; 17: 19214.
15.
NkhomaE.T., CoumbisJ., FarrA.M.No evidence of an association between efavirenz exposure and suicidality among HIV patients initiating antiretroviral therapy in a retrospective cohort study of real world data.Medicine2016; 95: e2480.
16.
SmithC., RyomL., MonforteA.Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study.J Int AIDS Soc2014; 17Suppl 2: 19512.
17.
KitahataM.M., RodriguezB., HaubrichR.Cohort profile: the Centers for AIDS research network of integrated clinical systems.Int J Epidemiol2008; 37: 948–955.
18.
Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (Updated 2016. Accessed 16 October 2017.) Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
19.
AkiskalH.S., BenazziF.Psychopathologic correlates of suicidal ideation in major depressive outpatients: is it all due to unrecognized (bipolar) depressive mixed states?Psychopathology2005; 38: 273–280.
20.
AshrafounL., PigeonW.R., ConnerK.R., LeongS.H., OslinD.W.Prevalence and correlates of suicidal ideation and suicide attempts among veterans in primary care referred for a mental health evaluation.J Affect Disord2016; 189: 344–350.
21.
KroenkeK., SpitzerR.L., WilliamsJ.B.The PHQ-9: validity of a brief depression severity measure.J Gen Intern Med2001; 16: 606–613.
22.
SpitzerR.L., KroenkeK., WilliamsJ.B.Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders.Patient Health Questionnaire. JAMA.1999; 282: 1737–1744.
WHO ASSIST Working Group.The alcohol, smoking and substance involvement screening test (ASSIST): development, reliability and feasibility.Addiction2002; 97: 1183–1194.
25.
HumeniukR., AliR., BaborT.F.Validation of the alcohol, smoking and substance involvement screening test (ASSIST).Addiction2008; 103: 1039–1047.
26.
ChesneyM.A., IckovicsJ.R., ChambersD.B.Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG).AIDS Care2000; 12: 255–266.
27.
AmicoK.R., FisherW.A., CornmanD.H.Visual analog scale of ART adherence: association with 3-day self-report and adherence barriers.J Acquir Immune Defic Syndr2006; 42: 455–459.
28.
VrouenraetsS.M., WitF.W., van TongerenJ., LangeJ.M.Efavirenz: a review.Expert Opin Pharmacother2007; 8: 851–871.
29.
BengtsonA.M., PenceB.W., CraneH.M.Disparities in depressive symptoms and antidepressant treatment by gender and race/ethnicity among people living with HIV in the United States.PLoS One2016; 11: e0160738.
30.
ChersichM.F., UrbanM.F., VenterF.W.Efavirenz use during pregnancy and for women of child-bearing potential.AIDS Res Ther2006; 3: 11.
31.
MirochnickM., BestB.M., ClarkeD.F.Antiretroviral pharmacology: special issues regarding pregnant women and neonates.Clin Perinatol2010; 37: 907–927.
32.
De SantisM., CarducciB., De SantisL., CavaliereA.F., StrafaceG.Periconceptional exposure to efavirenz and neural tube defects.Arch Intern Med2002; 162: 355.
33.
EatonE.F., TamhaneA.R., BurkholderG.A., WilligJ.H., SaagM.S., MugaveroM.J.Unanticipated effects of new drug availability on antiretroviral durability: implications for comparative effectiveness research.Open Forum Infect Dis2016; 3: ofw109.
34.
FDA notifications. Accelerated approval for raltegravir tablets.Aids Alert2007; 22: 143–144.
35.
JuethnerS.N., SeyfriedW., AbergJ.A.Tolerance of efavirenz-induced central nervous system side effects in HIV-infected individuals with a history of substance abuse.HIV Clin Trials2003; 4: 145–149.
36.
FumazC.R., Munoz-MorenoJ.A., MoltoJ.Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence.J Acquir Immune Defic Syndr2005; 38: 560–565.
37.
SteigbigelR.T., CooperD.A., KumarP.N.Raltegravir with optimized background therapy for resistant HIV-1 infection.N Engl J Med2008; 359: 339–354.
38.
D'AbbraccioM., BustoA., De MarcoM., FigoniM., MaddaloniA., AbresciaN.Efficacy and tolerability of integrase inhibitors in antiretroviral-naive patients.AIDS Rev2015; 17: 171–185.
39.
CotteL., FerryT., PuglieseP.Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - results from a large French multicenter cohort study.PLoS One2017; 12: e0170661.
KheloufF., AllemandJ., MokhtariS., DefaultA.Psychiatric disorders after starting dolutegravir: report of four cases.AIDS2015; 29: 1723–1725.
42.
ParantF., MiailhesP., BrunelF., GagnieuM.C.Dolutegravir-related neurological adverse events: a case report of successful management with therapeutic drug monitoring.Curr Drug Saf2018; 13: 69–71.
43.
ScheperH., van HoltenN., HovensJ., de BoerM.Severe depression as a neuropsychiatric side effect induced by dolutegravir.HIV Med2018; 19: e58–e59.
